Tatva Chintan Pharma Chem Limited

Tatva Chintan reported a robust Q1 FY26 with operating revenue reaching INR 1,169 million, marking an 11% year-on-year and 8% quarter-on-quarter increase. EBITDA surged to INR 173 million, reflecting a significant 37% year-on-year and 94% quarter-on-quarter growth. This strong performance led to an EBITDA margin expansion of 287 basis points year-on-year, reaching 14.8%, while PAT grew 26.9% YoY to INR 66 million.

The Pharma & Agro Intermediates and Specialty Chemicals (PASC) segment was a key growth driver, delivering INR 432 million in revenue, up 32% sequentially and 11% year-on-year. The Structure Directing Agents (SDA) segment also performed well, recording INR 394 million with 14% QoQ and 13% YoY growth. However, the Phase Transfer Catalyst (PTC) segment saw a 17% decline QoQ to INR 323 million, though it grew 9% YoY. Electrolyte Salts revenue increased 32% QoQ to INR 12 million, despite a 12% YoY dip.

Management reiterated its core focus on strengthening R&D capabilities, emphasizing scientific innovation as the most sustainable path to value creation. This approach is gaining recognition from customers, leading to interesting developmental opportunities. The company believes its strategic investments and customer-centric approach are well-aligned to capture long-term growth across critical markets.

Tatva Chintan is actively commercializing new products across segments. A new large agro intermediate is continuously being manufactured for Q3 orders, and a second agro intermediate has received commercial approval for supply starting in H2 FY26. In the semiconductor segment, successful pilot scale samples have been delivered, with slow commercialization expected to begin in 2027 and full-scale by 2029.

The SDA segment is experiencing a revival in demand, with increased visibility from key customers. Management expects continued revenue growth in coming quarters, supported by the upcoming implementation of Euro 7 norms. Orders for Euro 7 supplies are beginning from October, positioning this segment for significant growth, despite current pricing remaining at non-viable levels due to raw material costs.

The Electrolyte Salts segment is seeing a steady uptick from customers using its products in energy storage devices. The second approved product is being manufactured for dispatch this quarter, and a new customer for hybrid vehicles has approved material for extended validations. The company aims for this segment to contribute roughly 10% to the top line in the next financial years, with potential revenue of INR 15-20 crores from existing facilities.

The company announced the departure of its CFO, Mr. Ashok Bothra, who is relocating for another opportunity. Despite this change and persistent global geopolitical uncertainties, management expressed cautious optimism, noting a gradual recovery in export markets. They are confident in sustaining growth and delivering consistent performance in the quarters ahead, with clear visibility of orders until at least December.